| Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
HR | 95%CI | P | HR | 95%CI | P | |
Training cohort | ||||||
 Age(continuous) | 1.006 | 0.986 ~  1.025 | 0.574 | 1.004 | 0.985 ~  1.024 | 0.661 |
 Gender(male vs female) | 0.697 | 0.383 ~  1.268 | 0.240 |  |  |  |
 B4GALT1(high vs low) | 1.849 | 1.126 ~  3.035 | 0.016 | 1.773 | 1.075 ~  2.924 | 0.026 |
 CCI(≥2 vs ≤1) | 1.154 | 0.712 ~  1.872 | 0.563 |  |  |  |
 LVI(present vs absent) | 1.449 | 0.898 ~  2.339 | 0.131 |  |  |  |
 pN(N+ vs N-) | 1.651 | 0.718 ~  3.795 | 0.240 |  |  |  |
 pT stage | ||||||
  pT3 vs pT2 | 1.063 | 0.625 ~  1.808 | 0.824 |  |  |  |
  pT4 vs pT2 | 1.765 | 1.005 ~  3.100 | 0.049 |  |  |  |
 TNM stage | ||||||
  III vs II | 1.278 | 0.797 ~  2.051 | 0.312 | 1.220 | 0.759 ~  1.961 | 0.414 |
  IV vs II | 1.877 | 0.784 ~  4.492 | 0.159 | 1.636 | 0.680 ~  3.938 | 0.274 |
Validation cohort | ||||||
 Age(continuous) | 1.062 | 1.020 ~  1.105 | 0.004 | 1.050 | 1.006 ~  1.095 | 0.025 |
 Gender(male vs female) | 0.929 | 0.369 ~  2.337 | 0.876 |  |  |  |
 B4GALT1(high vs low) | 2.158 | 1.187 ~  3.923 | 0.012 | 1.862 | 1.016 ~  3.413 | 0.046 |
 CCI(≥2 vs ≤1) | 1.847 | 0.993 ~  3.438 | 0.054 |  |  |  |
 LVI(present vs absent) | 1.926 | 1.073 ~  3.456 | 0.029 | 1.060 | 0.458 ~  2.452 | 0.893 |
 pN(N+ vs N-) | 1.626 | 1.194 ~  2.213 | 0.002 |  |  |  |
 pT stage | ||||||
  pT3 vs pT2 | 2.708 | 1.426 ~  5.142 | 0.003 |  |  |  |
  pT4 vs pT2 | 2.517 | 0.967 ~  6.550 | 0.060 |  |  |  |
 TNM stage | ||||||
  III vs II | 3.291 | 1.471 ~  7.362 | 0.004 | 2.555 | 1.126 ~  5.796 | 0.026 |
  IV vs II | 6.290 | 2.874 ~  13.768 | < 0.001 | 5.230 | 1.962 ~  13.943 | 0.001 |